Article | June 22, 2021

Considerations For Early Stage Gene Therapy Start-Ups: From Clinical Development To Manufacturing To Commercialization

Gene Therapy

In 2020, nearly $20 billion of funding poured into the advanced therapy sector, reflecting the enthusiasm of researchers and investors in the transformative potential of these novel treatments.

Recently, Precision ADVANCE hosted Considerations for Early Stage Gene Therapy Start-ups: From Clinical Development to Manufacturing to Commercialization, an expert panel discussion moderated by Anshul Mangal, President of Project Farma and Precision ADVANCE. Precision ADVANCE is a collection of interconnected services and complementary teams uniquely focused on the complexities of gene therapies and the resources needed to bring these advanced therapeutics successfully to market.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: